Elizabeth Smyth

10PUBLICATIONS
14CO-AUTHORS
Predictive and prognostic markersTumour immunologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 24, 2024
Survival outcomes of Zo-NAnTAx: a five-year analysis of zoledronic acid added to a neoadjuvant regimen for HER2-positive breast cancer.

Bruno de Paula, Eliana Abdelhay, Carlos Augusto Moreira de Sousa

|Feb 08, 2023
Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer.

Bruno de Paula, Rosalind Kieran, Samantha Shui Yuan Koh

|Dec 23, 2022
Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer.

Susanne Crocamo, Renata Binato, Everton Cruz Dos Santos

|Aug 24, 2021
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group.

Thibaud Koessler, Maria Alsina, Dirk Arnold

|May 01, 2021
Personalising care in oesophageal cancer care with liquid biopsy.

Bruno De Paula, Elizabeth C Smyth

Pageof 2